



March 29, 2022

Yew Looi Liew  
President, U.S. Human Pharma  
Boehringer Ingelheim Pharmaceuticals, Inc.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877-0368

Dear Yew Looi Liew:

By letter dated October 4, 2021, HRSA instructed Boehringer Ingelheim Pharmaceuticals, Inc. (BI) to comply with its 340B statutory obligations and to immediately begin offering, without restrictions, BI's covered outpatient drugs at or below the 340B ceiling price to covered entities that dispense the discounted medications through their contract pharmacy arrangements. HRSA informed BI that continued failure to provide the 340B price to covered entities utilizing contract pharmacies could result in civil monetary penalties.

Given BI's continued refusal to comply,<sup>1</sup> HRSA has referred this issue to the HHS Office of the Inspector General in accordance with the 340B Program Ceiling Price and Civil Monetary Penalties Final Rule.<sup>2</sup>

Sincerely,

/S/

Emeka Egwim, PharmD, RPh  
LCDR, U.S. Public Health Service  
Director, Office of Pharmacy Affairs

<sup>1</sup> BI provided HRSA its basis for refusing to comply in a letter dated October 25, 2021.

<sup>2</sup> 82 Fed. Reg. 1210, 1230 (Jan. 5, 2017); 42 C.F.R. § 10.11(a).